A randomized, open label, controlled multicenter clinical study comparing the safety and efficacy of hydromorphone sustained-release tablets and hydrocodone sustained-release tablets in the treatment of elderly cancer pain patients in China

Start Date01 Jun 2026

Sponsor / Collaborator

Zhejiang Cancer Hospital

ChiCTR2600123148

/ Not yet recruitingPhase 4IIT

Analysis of the Efficacy of Different Doses of Dexmedetomidine Combined with Hydromorphone in Postoperative Pain Management for Lung Cancer

Start Date01 May 2026

Sponsor / Collaborator-

ChiCTR2600123852

/ Not yet recruitingPhase 4IIT

Comparison of Analgesic Efficacy and Opioid-Related Adverse Effects Between Oliceridine and Hydromorphone in Elderly Patients Undergoing Lumbar Spine Surgery: A Randomized, Controlled, Non-Inferiority Clinical Trial

Start Date01 May 2026

Sponsor / Collaborator

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

100 Clinical Results associated with Hydromorphone Hydrochloride

100 Translational Medicine associated with Hydromorphone Hydrochloride

100 Patents (Medical) associated with Hydromorphone Hydrochloride

3,302

Literatures (Medical) associated with Hydromorphone Hydrochloride

01 Jun 2026·Exploratory research in clinical and social pharmacy

Physicochemical compatibility and stability of ketamine co-administered with selected supportive care drugs and parenteral nutrition in pediatric oncology

Article

Author: Isaac, Emily ; Sunderland, Bruce ; Luna, Giuseppe ; Varonen, Katriina ; Soggee, Johnathan ; Martinez, Jorge ; Czarniak, Petra

Purpose:

Ketamine has been previously administered as an anesthetic but recently gained importance as an analgesic in pediatric oncology. Despite its efficacy, continuous intravenous administration to children with cancer is interrupted when other essential drugs require infusion. This occurs because its compatibility with many drugs and lipid emulsions is unknown, causing inadequate pain management and patient discomfort. This study has assessed the physicochemical compatibility and stability of ketamine with selected drugs, based on usage frequency data, and lipid emulsion formulations administered to pediatric cancer patients at tertiary hospitals.

Methods:

Physicochemical compatibility of ketamine involved admixture with selected concentrations of drugs, for physical incompatibility. Admixtures of ketamine with lipid emulsions and the other drugs included determining ketamine's chemical concentration using high performance liquid chromatography (HPLC). Particle size analysis investigated lipid stability.

Results:

The HPLC assay was linear over a range of concentrations (0.05 mg/mL - 0.5 mg/mL), validated under forced degradation conditions causing no interferences and an intra- and inter-day precision less than 2%. Ketamine was highly stable with all drugs and lipid emulsions tested, retaining >90% of its concentration for all systems investigated for two hours. No additional physical incompatibility occurred., but amoxicillin incompatibility was confirmed. Lipid emulsion stability was maintained, with no system exceeding particle size limits.

Conclusions:

Ketamine is safe to co-administer with AmBisome®, cyclizine, hydromorphone, Intralipid®, magnesium sulfate, metoclopramide, micafungin, potassium dihydrogen phosphate, sodium dihydrogen phosphate and vancomycin. Our findings are significant for improving pain management in vulnerable patients simultaneously administered the tested drugs with ketamine.

01 Jun 2026·Addictive behaviors reports

The efficacy and safety of short-acting, full agonist opioids for symptom management of opioid withdrawal

Review

Author: Lau, Anthony ; Kim, Jane J ; Budd, George ; Azar, Pouya ; Wong, Jade ; Siu, Jacky T P ; Baldwin, Kaitlyn ; Machado, Jessica

INTRODUCTION:

Patients with opioid use disorder often have undertreated withdrawal while in hospital, leading to high rates of premature discharges. Short-acting, full agonist opioids (SAFAOs) have been proposed to alleviate withdrawal symptoms when provided as adjuncts to opioid agonist therapy (OAT). We aimed to synthesize evidence on the safety and efficacy of SAFAOs.

METHODS:

We searched the scientific databases MEDLINE, Embase, CINAHL, PsycInfo, Web of Science Core Collection, and the Cochrane Library for studies with adults whose opioid withdrawal symptoms were treated with SAFAOs. Results were narratively synthesized.

RESULTS:

Our search yielded 5,616 papers screened and 15 studies included. Information was gathered mostly from patient charts, followed by cohort studies, a cross-sectional study, and a clinical trial. Hydromorphone, tramadol, fentanyl, and oxycodone were described individually or as groupings to reduce withdrawal from heroin or fentanyl, initiate OAT, or as a bridge to transition between medications. Most studies observed reduced withdrawal scores and fewer occurrences of premature discharges in those who received these medications. Oversedation was observed as an adverse event in patients with ongoing opioid use.

DISCUSSION:

This systematic review provides an up-to-date synthesis on the use of SAFAOs to treat withdrawal. Our results suggest that in-hospital use of SAFAOs can reduce patient suffering and potentially the following risk for premature discharges. More clinical studies are needed to further investigate the clinical utility of SAFAO as a combination treatment with OAT.

01 Jun 2026·PEDIATRIC BLOOD & CANCER

Low‐Dose Intravenous Ketamine for Primary Pain Control During Naxitamab Anti‐GD2 Immunotherapy Treatment

Article

Author: Szabo, Julienne ; Silber, Rosanna ; Fernandez, Nicole ; Modak, Shakeel ; Record, Benjamin ; Greenfield, Dana ; Hahn, Emily

ABSTRACT:

Background:

Anti‐GD2 antibodies, including naxitamab, are part of standard therapy for high‐risk neuroblastoma (HR‐NB) and are associated with significant pain. We developed a protocol for outpatient use of low‐dose intravenous ketamine (LDIVK) for pain management during naxitamab. We describe the LDIVK protocol and report on its impact on the management of naxitamab‐associated pain.

Methods:

Patients with HR‐NB receiving naxitamab with poorly controlled pain in at least 1 cycle received LDIVK outpatient for subsequent cycles. LDIVK at 0.5 mg/kg/h was started 30 minutes before and ended 1 hour after naxitamab. A retrospective chart review of LDIVK‐treated patients was completed. Intrapatient comparison of vital signs, opioid use, and adverse events between LVIDK‐containing and non‐containing cycles was analyzed using the Wilcoxon signed rank test.

Results:

Twenty‐two pediatric patients received LDIVK at a median age of 6.3 (range, 1–16) years. Twelve patients received the same premedication for cycles with and without LDIVK, and their opioid use was analyzed. Statistically significant reduction in total opioid use in LDIVK‐containing cycle (0.064 mg/kg IV hydromorphone vs. 0.054 mg/kg IV hydromorphone; p = 0.003) and rescue opioid use (0.028 mg/kg IV hydromorphone vs. 0.018 mg/kg IV hydromorphone; p = 0.0042) was noted. There was no significant difference in premedication opioid (0.046 mg/kg IV hydromorphone vs. 0.051 mg/kg IV hydromorphone; p > 0.2). Fluid boluses administered, heart rate, and blood pressure ( p > 0.1 for each) between cycles were the same. One patient experienced dysphoria, which resolved with LDIVK rate reduction.

Conclusion:

Ketamine was successfully administered in an outpatient setting and was associated with a significant opioid‐sparing effect. A larger prospective study is warranted.

News (Medical) associated with Hydromorphone Hydrochloride

19 Mar 2026

·www.einpresswire.com

RxActuator Acquisition Disrupts Veterinary Care with Multispecies 'Hospital-at-Home' Infusion Platform

Journey Legacy Partners acquires RxActuator to scale first non-powered, 48-hour wearable infusion system for multispecies home recovery We’re at a tipping point where staffing shortages, rising costs, and capacity limits are accelerating outpatient care—bringing hospital-grade infusion into the home with better outcomes and confidence” — Jeff Journey, CEO, RxActuator RALEIGH, NC, UNITED STATES, March 19, 2026 / EINPresswire.com / -- Journey Legacy Partners, LLC (JLP), a private investment and operating firm led by medical device and life sciences executive Jeff Journey, today announced the formation of Journey Actuating Technologies, Inc. (dba RxActuator) and the acquisition of 100% of the assets and intellectual property of RxActuator, Inc. and Medipacs. Backed by founder capital and execution-focused leadership, the acquisition marks the commercial relaunch of the RxActuator Mini-Infuser ® , a validated, commercial-stage platform positioned at the forefront of the rapidly expanding “hospital-at-home” movement in veterinary medicine. The RxActuator Mini-Infuser is the industry’s first wearable, disposable, non-powered continuous-rate infusion (CRI) system designed to bridge the gap between ICU-level care and the limitations of at-home oral dosing. The system enables reliable 48-hour continuous drug delivery for analgesics, antibiotics, and other critical therapies—allowing veterinarians to safely transition patients out of the clinic while improving patient comfort and outcomes. The device is powered by a patented, water-activated polymer actuator that delivers precise, constant-rate infusion without electronics, batteries, software, or programming—reducing complexity, cost, and failure risk. A secure mechanical locking mechanism further mitigates risks associated with controlled substances, supporting safe outpatient protocols. The platform has demonstrated real-world adoption, with approximately 500 units previously deployed across ~90 clinics in 26 U.S. states, as well as Canada and Australia. The acquisition includes proprietary polymer formulations, manufacturing tooling, clinical data, inventory, and global branding assets. The Mini-Infuser supports multiple clinical applications, including orthopedic recovery (e.g., TPLO procedures), time-dependent antimicrobial therapy, and hospice and palliative care, with planned expansion into equine medicine. Published pharmacokinetic (PK) studies demonstrate the system’s ability to maintain stable therapeutic drug concentrations over a 48-hour period, including: • Continuous pain management: Maintained steady-state plasma concentrations for hydromorphone above analgesic thresholds • Effective antimicrobial therapy: Maintained ceftazidime concentrations near target MIC (8 µg/mL) for 48 hours • Precise delivery: Constant-rate infusion of 10 mL over 48 hours with ±10% accuracy To support clinical adoption and future expansion of indications for use, RxActuator is establishing a Clinical Advisory Board composed of leading veterinary Key Opinion Leaders across orthopedic surgery, oncology, and palliative care. Additional information is available at www.rx-actuator.com . “We are entering the market at a clear inflection point where staffing shortages, rising costs, and capacity constraints are driving a shift toward outpatient care,” said Jeff Journey, CEO of RxActuator. “The Mini-Infuser enables that transition—moving infusion therapy into the home, unlocking ICU capacity, and delivering hospital-grade care with a better recovery experience for pets and greater peace of mind for their owners.” The company is executing a disciplined relaunch focused on scaling manufacturing, optimizing the supply chain, and reactivating commercial channels to meet demonstrated market demand. Execution-Focused Leadership The leadership team brings deep medical device, engineering, and commercial expertise: • Jeff Journey, CEO — 30+ years of leadership across Thermo Fisher Scientific, Johnson & Johnson MedTech, GE Aerospace, and the U.S. Air Force • Joshua Alcorn, Chief Commercial Officer — 15+ years of strategic healthcare, commercial, and operational leadership • Mark Banister, Consulting Technical Advisor — Original inventor of the core actuator technology and founder of RxActuator • Gary Knight, Consulting Technical Advisor — 35+ years of medical device engineering and manufacturing leadership Led by a team with extensive experience across global medical device organizations, RxActuator is also engaging with a select group of strategic and high-conviction investors as part of its seed-stage financing. About RxActuator (Journey Actuating Technologies, Inc.) Operating under Journey Actuating Technologies, Inc., RxActuator is a medical device company advancing multispecies hospital-at-home care through wearable, single-use continuous infusion systems. The platform enables veterinarians to improve clinical outcomes, increase operational efficiency, and deliver a superior recovery experience for both patients and their owners. Website: https://www.rx-actuator.com Jeff Journey Journey Legacy Partners, LLC jeffj@journeylegacypartners.com Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Acquisition

09 Jan 2026

·www.einpresswire.com

Analysis of WAC Price Changes Shows Modest Increases During Peak Adjustment Period

FAYETTEVILLE, NY, UNITED STATES, January 9, 2026 / EINPresswire.com / -- January is traditionally a peak period for pharmaceutical list price adjustments. The AnalySource team analyzed Wholesale Acquisition Cost (WAC) package pricing changes for all single-source prescription products with effective dates surrounding the new year, spanning December 1, 2025 through February 28, 2026. Overall, the analysis shows that most price changes were modest, though a limited number of notable outliers were observed. The analysis encompassed 1,902 National Drug Codes (NDCs) representing all identified single-source products with WAC package pricing changes during the analysis period. Only a small subset exhibited material pricing movement, with 11 drugs, some with various formulations, reporting WAC package price decreases and 31 products recording WAC package price increases of 10% or greater. These findings underscore that large price movements remain the exception rather than the norm, even during peak annual pricing cycles. Several significant outliers stood out in the data. Sandoz’s CIMERLI reported an 85.29% decrease in WAC package price, representing the largest reduction observed during the period. The largest WAC package price increase in the dataset was reported by PAI Holdings for TRIHEXYPHENIDYL (+480%). In addition, the most extreme WAC package price increases were highly concentrated within a small number of manufacturers, with Hospira/Pfizer accounting for the majority of increases exceeding 300%, including Verapamil HCl (+377%), Lorazepam (+346%), Naloxone HCl (+334%), and Hydromorphone HCl (+318%). These products are commonly used in hospital and acute care settings, where pricing dynamics may differ from those of outpatient or retail-dispensed therapies. Other notable movements included Sprout Pharmaceuticals, which reported a 110.64% increase for ADDYI, a branded product indicated for sexual function disorders. Novo Nordisk implemented substantial price decreases across multiple insulin products, including Fiasp and Tresiba presentations, reflecting a coordinated portfolio-level pricing adjustment rather than isolated product changes. Several manufacturers exhibited mixed pricing strategies within their portfolios. Boehringer Ingelheim reported modest price increases for products such as Ofev, Pradaxa, and Gilotrif while simultaneously implementing price decreases of approximately 44% for several other products. Pfizer reported both significant price increases across select hospital and specialty products and a price decrease for Xeljanz, a therapy used in inflammatory conditions. Outside of these exceptions, most manufacturers reported modest WAC package price increases in the range of 2% to 6%, consistent with historical annual pricing patterns. Across therapeutic areas, these adjustments align with routine pricing activity that may reflect product lifecycle stage, competitive dynamics, manufacturing considerations, and regulatory developments. While additional list price adjustments are expected later in the pricing cycle, early indications suggest that the majority of products will continue to reflect modest pricing changes, with large increases and decreases remaining relatively limited. The AnalySource team will continue to monitor these developments closely and will provide further updates as additional information becomes available. Daniel Miccio DMD America, Inc. +1 315-400-2289 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultFinancial Statement

01 Jan 2026

·pharma.economictimes.indiatimes.com

Drugmakers raise US prices on 350 medicines despite pressure from Trump

New York: Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster ⁠cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors . The number of price increases for 2026 is up from the same point last year, when drugmakers unveiled plans for raises on more than 250 drugs. The median of this year's price hikes is around 4% - in line ‌with 2025. The increases do ‌not reflect any rebates to pharmacy benefit managers and other discounts. DRUGMAKERS ALSO CUT SOME PRICES Drugmakers also plan to cut the list prices on around nine drugs. That includes a more than 40% cut for ‌Boehringer Ingelheim's diabetes drug Jardiance and three related treatments. Boehringer Ingelheim and Eli Lilly, which sell Jardiance together, did not immediately respond to requests for comment on the reason for the price cuts. Jardiance is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026. Under those negotiations, Boehringer and Lilly slashed the Jardiance price by two-thirds. U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay in similarly wealthy nations. The increases on 350 medicines come even as Trump has struck deals with 14 ‌drugmakers on prices of ‍some of their medicines for the government's Medicaid program for low-income Americans and for cash payers. Pfizer, Sanofi, Boehringer Ingelheim, Novartis ‍and GSK are among those companies and also plan to raise prices on some drugs on ‌January 1. "These deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.," said Dr. Benjamin Rome, a health policy researcher at Brigham and Women's Hospital in Boston. Rome said the companies seem to be maximizing prices while negotiating discounts behind the scenes with health and drug insurers and then setting yet another price for direct-to-consumer cash-pay sales. An HHS spokesman declined to comment. KEEPING UP WITH INFLATION Pfizer announced the most list price hikes, on around 80 different drugs including cancer drug Ibrance, migraine pill Nurtec, and COVID treatment Paxlovid, as well as some administered in hospitals such as morphine and hydromorphone. Most of Pfizer's increases ‍are below 10%, except for a 15% hike of COVID vaccine Comirnaty, while some of its relatively inexpensive hospital drugs saw more than four-fold increases. Pfizer said in a statement it had adjusted the average list price of its innovative medicines and vaccines ‍for 2026 below the ⁠overall rate of inflation. "The modest increase is ⁠necessary to support investments that allow us to continue to discover and deliver new medicines as well as address increased costs throughout our business," the company said. Larger U.S. drug price increases were once far more common. Drugmakers have scaled them back due to criticism from lawmakers and new government policies, such as penalizing companies that charge Medicare program prices that rise faster than inflation. European drugmaker GSK plans to increase prices on around 20 drugs and vaccines from 2% to 8.9%. The drugmaker said it is committed to reasonable prices and the hikes are needed to support scientific innovation. Sanofi and Novartis did not respond to requests for comment. More price hikes and cuts can be expected in early January, which is historically the biggest month for drugmakers to raise prices. 3 Axis is a consulting firm that works with pharmacist groups, health plans and some pharmaceutical industry-related groups on drug pricing and supply chain issues. It is a related entity to, and shares staff with, drug pricing non-profit 46brooklyn. (Reporting by Michael Erman ; editing by Caroline Humer)

Vaccine

100 Deals associated with Hydromorphone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00839	Hydromorphone Hydrochloride	N02AA03	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Severe pain	United States	Hikma Pharmaceuticals USA, Inc.	14 Dec 2023
Cancer Pain	Japan	Daiichi Sankyo Co., Ltd.	01 Jun 2017
Pain, Postoperative	United States	SpecGx LLC	01 Mar 2010
Pain	United States	Fresenius Kabi USA LLC	11 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	-	ALZA Corp.	13 Dec 2006
Chronic osteoarthritis	Phase 3	-	ALZA Corp.	14 Nov 2006
Chronic Pain	Phase 3	United States	Purdue Pharma LP	01 Jul 2005
Osteoarthritis, Hip	Phase 3	-	ALZA Corp.	01 Nov 2003
Osteoarthritis, Knee	Phase 3	-	ALZA Corp.	01 Nov 2003
Anesthesia	Phase 3	-	Johnson & Johnson	-
Acute Pain	Phase 2	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 2025
Chest Pain	Phase 2	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 2025
Analgesia	Phase 2	-	ALZA Corp.	14 Dec 2006
Early Stage Breast Carcinoma	Phase 1	China	Xian-Janssen Pharmaceutical Ltd.	01 Dec 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03726268 (OSPREy, CTgov)	Phase 4	Pain, Postoperative	907	Methadone (Short-stay, IV Methadone)	giehkpdnch(cxowythnhz) = vbclcepguc fspntfednz (wzltharsnn, 15.50) View more	-	19 Nov 2025
				Fentanyl+Hydromorphone+Sufentanil+Morphine (Short-stay, IV Short-acting Opioids)	giehkpdnch(cxowythnhz) = cvcnubsykz fspntfednz (wzltharsnn, 11.60) View more
ESMO2025	Not Applicable	Neoplasms	371	Subcutaneous hydromorphone PCA	qkmdyqunep(wyfdoeadco) = No case of interruption occurred, and all the patients were satisfied with pain control. uvbtcttgoe (tbdajwgcnf ) View more	Positive	17 Oct 2025
NCT03592992 (Pubmed \| Anesth Analg)	Phase 4	Analgesia	126	Hydromorphone 75 μg	vzwghaxanx(ipnkcgtlll) = iglocuuapc iealqwcben (qahquqtafe, 1.5) View more	Non-inferior	10 Jun 2025
				Morphine 150 μg	vzwghaxanx(ipnkcgtlll) = nejjfndaoi iealqwcben (qahquqtafe, 1.7) View more
NCT04752033 (Pubmed \| Mayo Clin Proc Innov Qual Outcomes)	Phase 4	Pain, Postoperative	-	Intrathecal Morphine	khigikabgp(yimjbwavgb) = No serious adverse events were observed throughout the study duration lmamegiayj (cfubjeuflh ) View more	Negative	01 Apr 2025
				Intrathecal Hydromorphone
NCT04300231 (CTgov)	Phase 3	Pain, Postoperative	160	/hydromorphone 0.05mg/ml+bupivacaine (Thoracic Epidural)	gpvumeanwr(vtcsdoeszy) = exbqjpcaph tirsavefwy (xbyqdzvoqs, qgrncikhgb - jqadelszqt) View more	-	10 Feb 2025
				injectable saline+Liposomal bupivacaine+bupivacaine (Rectus Sheath Block)	gpvumeanwr(vtcsdoeszy) = gojsrpbxgh tirsavefwy (xbyqdzvoqs, joniwguvqf - ucwtarkxua) View more
NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	cugnryktcv = ogrhkwpoyy unawtvyyth (lggheeqtgk, ezmddwsacd - mczxnqjwas) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	cugnryktcv = eutywzabtm unawtvyyth (lggheeqtgk, imrqksucxm - ownxjuhaiw) View more
NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	yayiwoeafo(vpohryfbyn) = pzxqmsacoa hhwwiqmdhi (hscfqxooyj, jbldfmdwrg - euncdrnmpt) View more	-	17 Oct 2024
NCT04258631 (CTgov)	Phase 4	Female Genital Neoplasms \| Pain	105	Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine))	tyknuyyzgz(tjxvpymwgg) = haicjpyzwa srzspxvypy (oyxwuskkwm, zjhyqukgal - tjdbuqkewl) View more	-	16 Oct 2024
				Laparotomy+Hydromorphone+Liposomal Bupivacaine (Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone))	tyknuyyzgz(tjxvpymwgg) = kfyfraqclf srzspxvypy (oyxwuskkwm, qvqvtzeexm - cpfoofabzo) View more
NCT02939209 (Pubmed \| Can Anaesth Soc J)	Phase 4	-	73	Hydromorphone 2 mg	typteqivap(grgbrhqytu) = vmvusyegpn jvcrwdmamg (cszzdfvbsx, 2.4)	Negative	01 Jun 2024
				Placebo	typteqivap(grgbrhqytu) = jhyvuqwbom jvcrwdmamg (cszzdfvbsx, 2.3)
NCT04296305 (ASCO2024)	Phase 4	Cancer Pain	-	IV hydromorphone 1mg over 15 minutes	dsszxcpwly(dalmupweal) = Drowsiness was more frequent in the standard group than the experimental group (50% vs 29% at 15 minutes, and 52% vs 31% at 60 minutes) fwqswyjzjv (pfknlvjdsf )	Positive	24 May 2024
				IV hydromorphone 1mg over 2 minutes

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis